| __timestamp | Apellis Pharmaceuticals, Inc. | Vertex Pharmaceuticals Incorporated |
|---|---|---|
| Wednesday, January 1, 2014 | 2908166 | 305409000 |
| Thursday, January 1, 2015 | 6356782 | 377080000 |
| Friday, January 1, 2016 | 4303743 | 432829000 |
| Sunday, January 1, 2017 | 10463151 | 496079000 |
| Monday, January 1, 2018 | 22639184 | 557616000 |
| Tuesday, January 1, 2019 | 67046483 | 658498000 |
| Wednesday, January 1, 2020 | 139401000 | 770456000 |
| Friday, January 1, 2021 | 176771000 | 840100000 |
| Saturday, January 1, 2022 | 277163000 | 944700000 |
| Sunday, January 1, 2023 | 500815000 | 1136600000 |
| Monday, January 1, 2024 | 1464300000 |
Unleashing the power of data
In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for sustaining growth and innovation. This analysis compares the SG&A expenses of Vertex Pharmaceuticals Incorporated and Apellis Pharmaceuticals, Inc. from 2014 to 2023.
Vertex Pharmaceuticals, a leader in cystic fibrosis treatments, consistently outspent Apellis, with SG&A expenses peaking at approximately $1.14 billion in 2023, marking a 272% increase from 2014. Meanwhile, Apellis, known for its work in complement-mediated diseases, saw a staggering 17,000% rise in SG&A expenses, reaching around $500 million in 2023.
This dramatic increase for Apellis reflects its aggressive expansion and investment in marketing and administrative capabilities. In contrast, Vertex's steady growth underscores its established market presence and strategic financial management. Understanding these trends offers valuable insights into the financial strategies of leading biotech firms.
Novo Nordisk A/S or Vertex Pharmaceuticals Incorporated: Who Manages SG&A Costs Better?
Operational Costs Compared: SG&A Analysis of Vertex Pharmaceuticals Incorporated and Regeneron Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? Vertex Pharmaceuticals Incorporated or Blueprint Medicines Corporation
Vertex Pharmaceuticals Incorporated vs Sarepta Therapeutics, Inc.: SG&A Expense Trends
Vertex Pharmaceuticals Incorporated vs Evotec SE: SG&A Expense Trends
Takeda Pharmaceutical Company Limited vs Apellis Pharmaceuticals, Inc.: SG&A Expense Trends
Comparing SG&A Expenses: argenx SE vs Apellis Pharmaceuticals, Inc. Trends and Insights
Breaking Down SG&A Expenses: United Therapeutics Corporation vs Apellis Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc. vs Apellis Pharmaceuticals, Inc.: SG&A Expense Trends
Apellis Pharmaceuticals, Inc. and ImmunityBio, Inc.: SG&A Spending Patterns Compared
Apellis Pharmaceuticals, Inc. or Soleno Therapeutics, Inc.: Who Manages SG&A Costs Better?
Cost Management Insights: SG&A Expenses for Apellis Pharmaceuticals, Inc. and Evotec SE